Center for Alcohol and Substance Use Studies, Rutgers, the State University of New Jersey, Piscataway, NJ, United States of America.
Department of Psychiatry, the University of Mississippi Medical Center, Jackson, MS, United States of America.
J Subst Use Addict Treat. 2023 Mar;146:208957. doi: 10.1016/j.josat.2023.208957. Epub 2023 Jan 24.
Screening, brief intervention, and referral to treatment (SBIRT) has been used to change substance use behavior. Despite cannabis being the most prevalent federally illicit substance, we have limited understanding of use of SBIRT for managing cannabis use. This review aimed to summarize the literature on SBIRT for cannabis use across age groups and contexts over the last two decades.
This scoping review followed the a priori guide outlined by the PRISMA (Preferred Reporting Items for Scoping Reviews and Meta-Analyses) statement. We gathered articles from PsycINFO, PubMed, Sage Journals Online, ScienceDirect, and SpringerLink.
The final analysis includes forty-four articles. Results indicate inconsistent implementation of universal screens and suggest screens assessing cannabis-specific consequences and utilizing normative data may increase patient engagement. Broadly, SBIRT for cannabis demonstrates high acceptability. However, the impact of SBIRT on behavior change across various modifications to intervention content and modality has been inconsistent. In adults, patients with primary cannabis use are not engaging in recommended treatment at similar rates to other substances. Results also suggest a lack of research addressing referral to treatment in adolescents and emerging adults.
Based on this review, we offer several to improve each component of SBRIT that may increase implementation of screens, effectiveness of brief interventions, and engagement in follow-up treatment.
筛查、简短干预和转介治疗(SBIRT)已被用于改变物质使用行为。尽管大麻是最常见的联邦非法物质,但我们对管理大麻使用的 SBIRT 用法的了解有限。本综述旨在总结过去二十年中不同年龄组和背景下使用 SBIRT 治疗大麻使用的文献。
本范围综述遵循 PRISMA(用于范围综述和荟萃分析的首选报告项目)声明中概述的预先制定的指南。我们从 PsycINFO、PubMed、Sage Journals Online、ScienceDirect 和 SpringerLink 收集文章。
最终分析包括 44 篇文章。结果表明,普遍筛查的实施不一致,并表明筛查评估大麻特异性后果并利用规范数据可能会增加患者的参与度。总体而言,大麻的 SBIRT 具有很高的可接受性。然而,干预内容和模式的各种修改对行为改变的影响不一致。在成年人中,主要使用大麻的患者参与推荐治疗的比例与其他物质不同。结果还表明,缺乏针对青少年和新兴成年人转介治疗的研究。
基于本综述,我们提出了一些建议来改进 SBIRT 的每个组成部分,这可能会增加筛查的实施、简短干预的有效性以及对后续治疗的参与度。